PE20240687A1 - Compuestos de indazol como inhibidores de cinasas - Google Patents
Compuestos de indazol como inhibidores de cinasasInfo
- Publication number
- PE20240687A1 PE20240687A1 PE2023001961A PE2023001961A PE20240687A1 PE 20240687 A1 PE20240687 A1 PE 20240687A1 PE 2023001961 A PE2023001961 A PE 2023001961A PE 2023001961 A PE2023001961 A PE 2023001961A PE 20240687 A1 PE20240687 A1 PE 20240687A1
- Authority
- PE
- Peru
- Prior art keywords
- carbon atom
- membered
- alkyl
- ring
- optionally substituted
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 8
- 150000001721 carbon Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula (I), o una sal farmaceuticamente aceptable del mismo, donde n = 1, 2 o 3; m = 0, 1, 2 o 3; cada R1 es independientemente H, CN o alquilo C1-C6 opcionalmente sustituido; cada R2 es independientemente H, CN o alquilo C1-C6 opcionalmente sustituido; o dos grupos R1 unidos al mismo atomo de carbono, junto con el atomo de carbono al que ambos estan unidos forman un anillo espirocicloalquilo de 3-7 miembros opcionalmente sustituido o un anillo espiroheterocicloalquilo de 3-7 miembros opcionalmente sustituido; o dos grupos R1 unidos al mismo atomo de carbono, junto con ese atomo de carbono, representan un grupo carbonilo (C=O); o dos grupos R2 unidos al mismo atomo de carbono, junto con el atomo de carbono al que ambos estan unidos forman un anillo espirocicloalquilo de 3-7 miembros opcionalmente sustituido o un anillo espiroheterocicloalquilo de 3-7 miembros opcionalmente sustituido; o dos grupos R2 unidos al mismo atomo de carbono, junto con ese atomo de carbono, representan un grupo carbonilo (C=O); o dos grupos R1 unidos a diferentes atomos de carbono, junto con los atomos de carbono a los que estan unidos, forman un anillo cicloalquilo de 3-7 miembros; o dos grupos R2 unidos a diferentes atomos de carbono, junto con los atomos de carbono a los que estan unidos, forman un anillo cicloalquilo de 3-7 miembros; o un grupo R1 y un grupo R2 estan unidos para formar un anillo biciclico puenteado de 6-9 miembros; A = N o CH; Z = S(O)2; S(O); O, entre otros; Y es un anillo heteroarilo de 5 o 6 miembros o un anillo arilo de 6 miembros; Q5, Q6, Q7, Q8 y Q9, son cada uno independientemente N o CR5, en donde uno o dos de Q5, Q6, Q7, Q8 y Q9 son N y el resto son CR5; R5 es H, halogeno, alquilo C1-C3, entre otros; X = O, S o NR, en donde R es H o alquilo C1-C3; R6 es alquilo C1-C6; R7 es H, halogeno, -alquilo C1-C6, entre otros; y R8 es H, halogeno, -alquilo C1-C6, entre otros. Asimismo, sus composiciones farmaceuticas que incluyen uno o mas de dichos compuestos de indazol o una sal farmaceuticamente aceptable del mismo, y un excipiente farmaceuticamente aceptable son utiles en el tratamiento del cancer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063132031P | 2020-12-30 | 2020-12-30 | |
US202163216879P | 2021-06-30 | 2021-06-30 | |
PCT/US2021/065679 WO2022147246A1 (en) | 2020-12-30 | 2021-12-30 | Indazole compounds as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240687A1 true PE20240687A1 (es) | 2024-04-10 |
Family
ID=80168316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001961A PE20240687A1 (es) | 2020-12-30 | 2021-12-30 | Compuestos de indazol como inhibidores de cinasas |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240109865A1 (es) |
EP (1) | EP4271673A1 (es) |
JP (1) | JP2024502433A (es) |
KR (1) | KR20230152654A (es) |
AU (1) | AU2021411587A1 (es) |
CA (1) | CA3205986A1 (es) |
CL (1) | CL2023001951A1 (es) |
CO (1) | CO2023008689A2 (es) |
CR (1) | CR20230325A (es) |
EC (1) | ECSP23048136A (es) |
IL (1) | IL304014A (es) |
MX (1) | MX2023007793A (es) |
PE (1) | PE20240687A1 (es) |
TW (1) | TW202241906A (es) |
WO (1) | WO2022147246A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024006897A1 (en) * | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Indazole compounds |
WO2024006883A1 (en) * | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
WO2024050396A1 (en) | 2022-08-30 | 2024-03-07 | Tyra Biosciences, Inc. | Methods of treating solid tumors having activating fgfr3 gene alterations |
WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
SG177225A1 (en) | 2006-12-01 | 2012-01-30 | Agency Science Tech & Res | Cancer-related protein kinases |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
CN102243505B (zh) | 2011-07-07 | 2013-08-14 | 矽力杰半导体技术(杭州)有限公司 | 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路 |
JP6036693B2 (ja) | 2011-08-05 | 2016-11-30 | アステラス製薬株式会社 | 新規fgfr4変異体の検出法 |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
CN103420906B (zh) * | 2012-05-21 | 2015-09-09 | 南京圣和药业股份有限公司 | 新型酪氨酸蛋白激酶抑制剂 |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
ES2949394T3 (es) | 2012-11-05 | 2023-09-28 | Found Medicine Inc | Moléculas de fusión novedosas y usos de las mismas |
CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2015008844A1 (ja) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
US10323285B2 (en) | 2013-09-09 | 2019-06-18 | Nantomics, Llc | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods |
CN109706222A (zh) | 2013-12-11 | 2019-05-03 | 安可济控股有限公司 | 用于检测罕见序列变体的组合物和方法 |
WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬 |
US20160340742A1 (en) | 2014-02-04 | 2016-11-24 | Mayo Foundation For Medical Education And Research | Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients |
DK3125936T3 (da) | 2014-03-31 | 2019-08-05 | Debiopharm Int Sa | Fgfr-fusioner |
KR20170044172A (ko) | 2014-08-28 | 2017-04-24 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 조성물을 사용하여 급성 골수성 백혈병 또는 급성 림프구성 백혈병을 치료하는 방법 |
JP2018027019A (ja) | 2014-11-26 | 2018-02-22 | 国立研究開発法人国立がん研究センター | 胆道がんにおける新規治療標的融合遺伝子 |
CN107223163A (zh) | 2014-12-24 | 2017-09-29 | 豪夫迈·罗氏有限公司 | 用于膀胱癌症的治疗,诊断和预后方法 |
EP3265462A1 (en) | 2015-03-03 | 2018-01-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fgfr3 antagonists |
US10519133B2 (en) * | 2015-08-07 | 2019-12-31 | Medshine Discovery Inc. | Vinyl compounds as FGFR and VEGFR inhibitors |
WO2021138391A1 (en) * | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
-
2021
- 2021-12-30 KR KR1020237024903A patent/KR20230152654A/ko unknown
- 2021-12-30 MX MX2023007793A patent/MX2023007793A/es unknown
- 2021-12-30 US US18/259,422 patent/US20240109865A1/en active Pending
- 2021-12-30 JP JP2023540770A patent/JP2024502433A/ja active Pending
- 2021-12-30 PE PE2023001961A patent/PE20240687A1/es unknown
- 2021-12-30 WO PCT/US2021/065679 patent/WO2022147246A1/en active Application Filing
- 2021-12-30 CR CR20230325A patent/CR20230325A/es unknown
- 2021-12-30 AU AU2021411587A patent/AU2021411587A1/en active Pending
- 2021-12-30 TW TW110149633A patent/TW202241906A/zh unknown
- 2021-12-30 EP EP21852113.6A patent/EP4271673A1/en active Pending
- 2021-12-30 CA CA3205986A patent/CA3205986A1/en active Pending
- 2021-12-30 IL IL304014A patent/IL304014A/en unknown
-
2023
- 2023-06-26 EC ECSENADI202348136A patent/ECSP23048136A/es unknown
- 2023-06-30 CO CONC2023/0008689A patent/CO2023008689A2/es unknown
- 2023-06-30 CL CL2023001951A patent/CL2023001951A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4271673A1 (en) | 2023-11-08 |
US20240109865A1 (en) | 2024-04-04 |
KR20230152654A (ko) | 2023-11-03 |
TW202241906A (zh) | 2022-11-01 |
MX2023007793A (es) | 2023-09-22 |
JP2024502433A (ja) | 2024-01-19 |
WO2022147246A1 (en) | 2022-07-07 |
CA3205986A1 (en) | 2022-07-07 |
CR20230325A (es) | 2023-12-11 |
AU2021411587A1 (en) | 2023-07-06 |
CO2023008689A2 (es) | 2023-09-29 |
ECSP23048136A (es) | 2023-09-29 |
CL2023001951A1 (es) | 2023-12-01 |
IL304014A (en) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240687A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR120855A1 (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
AR113820A1 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
AR076235A1 (es) | Compuestos organicos y sus usos | |
PE20231311A1 (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos | |
AR114828A1 (es) | Compuestos de pteridinona y sus usos | |
AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
PE20240691A1 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
AR113933A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina | |
PE20240775A1 (es) | Compuestos antivirales | |
AR121676A1 (es) | DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1 |